MindBio CEO Details AI Voice Detection for Workplace Safety on Podcast

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company at the forefront of AI-driven voice analysis for intoxication detection, recently shared its commercialization roadmap during a TechMediaWire Podcast appearance. Founder and CEO Justin Hanka detailed how the company’s platform uses advanced machine learning models trained on over 50 million data points from years of clinical and behavioral research. The technology can detect not only alcohol intoxication but also the influence of drugs such as cannabis, cocaine, opioids, and psychedelics by analyzing subtle physiological indicators in a person’s voice. MindBio’s initial focus is on high-risk workplace safety sectors like mining, aviation, and construction, where impairment-related incidents pose significant operational and regulatory risks. Management expects live workplace testing deployments to begin in the second quarter of 2026 as the company transitions from development to commercial implementation.

The podcast appearance, which can be accessed via this link, highlighted MindBio’s decade-long investment in drug and alcohol research, during which it collected extensive speech datasets. With recent advances in AI and machine learning, the company has developed models capable of identifying intoxication with high accuracy through non-invasive voice analysis. Hanka emphasized that the platform goes beyond alcohol detection, encompassing a broad range of central nervous system-affecting substances. This capability positions MindBio as a potential game-changer in workplace safety, where existing drug testing methods can be invasive, time-consuming, or limited in scope. The company views its technology as part of a broader AI-driven diagnostics platform that could eventually support health and wellness applications beyond intoxication monitoring.

For investors seeking the latest updates, the company’s newsroom is available at https://ibn.fm/MBQIF. MindBio’s commercial strategy targets industries with stringent safety requirements, aiming to reduce accidents and liability associated with impairment. As the company moves toward Q2 2026 deployments, it is actively engaging with potential partners in the mining, aviation, and construction sectors. The technology’s ability to detect multiple substances through a simple voice sample could streamline testing procedures and enhance safety protocols. This approach aligns with growing demand for non-invasive, rapid, and accurate impairment screening methods. MindBio’s progress in this space underscores the potential of voice analytics to transform occupational health and safety.